Across TCGA pan-cancer cohorts, RGS1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RGS1 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher RGS1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RGS1 expression acts as an unfavorable survival marker.
COAD, UCEC, and HNSC are the cancer types where RGS1 Mutation most reproducibly stratifies survival.